About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...
SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Aptose Biosciences (APTO) announced the publication of preclinical data for Aptose’s lead hematology compound tuspetinib in Cancer Research ...
A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...
Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic ...
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...
Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and ...